Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole versus daptomycin for Staphylococcus aureus bacteremia including infective endocarditis
2017-001699-43Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Staphylococcal bacteremia and endocarditis (IE) comparing Ceftobiprole medocaril arm with Daptomycin arm (2 arms). Primary endpoint: Overall success at post-treatment evaluation. Started Aug 2018; status: completed.
02
Drugs
ceftobiprole medocarildaptomycin
03
Conditions
Staphylococcal bacteremiaendocarditis (IE)
Beyond the preview
Go deeper on 2017-001699-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001699-43.